Edit Module

Virbac Unveils Canine Cephalexin Tablet

Posted: Sept. 5, 2012, 8:05 p.m. EDT



Published:

Virbac Animal Health of Fort Worth, Texas, launched the first chewable cephalexin tablet designed exclusively for dogs, the company reported Tuesday.

The FDA-approved drug, called Rilexine, is indicated for the treatment of secondary superficial bacterial pyoderma in dogs caused by susceptible strains of Staphylococcus pseudintermedius.

Previously, veterinarians often relied on the generic human form of cephalexin to treat dogs, but Rilexine is the first drug of its kind approved by the U.S. Food and Drug administration for the veterinary market, Virbac reported. The new drug should overcome some of the drawbacks of prescribing human cephalexin off-label, including a bitter, metallic taste and strong odor, a lack of veterinary-specific guidelines and the inability to tailor doses, Virbac noted.

Pyoderma is one of the most common diseases seen in dogs, and secondary superficial bacterial pyoderma is the most common form of pyoderma, according to Virbac.

Rilexine is available in 150 mg, 300 mg and 600 mg scored doses. The drug should not be prescribed to dogs that have a known allergy to cephalexin or the B-lactam group of antibiotics.

<HOME>

Edit Module
Edit ModuleShow Tags

Archive »Read More

The Idea Competition Sparks Veterinary Student Innovation

One contest leads three student teams to win prizes to fund ongoing development of their new industry product concepts.

Zoetis, AAVMC Announce 315 Scholarships to Vet Students

The winners of the 2017 Zoetis Veterinary Student Scholarship Program were presented at the 2017 Student American Veterinary Medical Association.

IDEXX Initiative Seeks to Minimize Radiation Risks

Lower the Dose aims to help the veterinary industry improve in-practice radiation safety.

Add your comment:
Edit Module
Edit Module
Edit ModuleEdit ModuleShow Tags Edit Module
Edit Module Edit Module
Edit ModuleShow Tags

Events


Show More...
Edit Module
Edit Module